SCHEMBL5215495

SCHEMBL5215495

Clc1ccc(-n2cc(-c3ccncn3)cn2)c2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.40
GRM4 Q14833 6/20 0.37
JAK2 O60674 1/20 0.37
DCLK1 O15075 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
EGFR P00533 1/20 0.35
PRKACA P17612 1/20 0.35
FLT3 P36888 1/20 0.35
FRK P42685 1/20 0.35
MAPK9 P45984 1/20 0.35
CSNK1A1 P48729 1/20 0.35
GSK3B P49841 1/20 0.35
MINK1 Q8N4C8 1/20 0.35
SLK Q9H2G2 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
MAP4K5 Q9Y4K4 1/20 0.35
DYRK1B Q9Y463 3/20 0.35
MKNK1 Q9BUB5 1/20 0.35
HTR2B P41595 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216999 0.86 GRM5 (0.46) PDE10AGRM4JAK2FLT3HTR2B
SCHEMBL5221469 0.78 NPC1 (0.47) GRM4HTR2BMTNR1AKCNH2HCAR1
SCHEMBL5670069 0.75 PDE10A (0.42) PDE10AGRM4MAPK9DYRK1BHTR2B
SCHEMBL101224 0.74 PRKCI (0.60) PDE10AGRM4JAK2PRKD3MAP4K4
SCHEMBL29540790 0.74 PRKCI (0.60) PDE10AGRM4JAK2PRKD3MAP4K4
SCHEMBL5220318 0.73 DYRK1B (0.41) PDE10AGRM4DYRK1BGRM5CYP1A2
SCHEMBL5216560 0.73 DYRK1B (0.44) PDE10AGRM4JAK2DYRK1BMKNK1
SCHEMBL5218142 0.72 PDE10A (0.42) PDE10AGRM4JAK2DCLK1PRKD3
SCHEMBL5220201 0.72 AHR (0.42) GRM4JAK2HTR2BMTNR1AKCNH2
SCHEMBL5668065 0.72 GRM4 (0.48) PDE10AGRM4MAPK9MKNK1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C PDE10A 964/4885GRM4 8/4885JAK2 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.